P/B
0,9
Protara Therapeutics
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
$146.6M
Market Cap • 10/30/2026
2006
(20 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,7
EPS
—
Market Cap
Market Cap
146,6M
EV
6,8M
EV/Revenue
0
EV/EBITDA
-0,1
EV/EBIT
-0,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-56,6%
Total Yield
-56,6%
Payout
0%
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
105%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
2,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
12,1%
CAGR Net Income 5Y
10,2%
CAGR EPS 5Y
-22,4%
CAGR OCF 5Y
15,7%
Leverage
N.D./EBITDA
1,8
Debt/Equity
0%
Current Ratio
11
Quick Ratio
10,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!